The latest price target for Bristol-Myers Squibb (NYSE:BMY) was reported by Morgan Stanley on December 12, 2025. The analyst firm set a price target for $37.00 expecting BMY to fall to within 12 months (a possible -29.54% downside). 20 analyst firms have reported ratings in the last year.

The latest analyst rating for Bristol-Myers Squibb (NYSE:BMY) was provided by Morgan Stanley, and Bristol-Myers Squibb maintained their underweight rating.

The last upgrade for Bristol-Myers Squibb Co happened on December 12, 2025 when Guggenheim raised their price target to $62. Guggenheim previously had a neutral for Bristol-Myers Squibb Co.

The last downgrade for Bristol-Myers Squibb Co happened on April 8, 2025 when Goldman Sachs changed their price target from $67 to $55 for Bristol-Myers Squibb Co.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bristol-Myers Squibb, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bristol-Myers Squibb was filed on December 12, 2025 so you should expect the next rating to be made available sometime around December 12, 2026.

While ratings are subjective and will change, the latest Bristol-Myers Squibb (BMY) rating was a maintained with a price target of $36.00 to $37.00. The current price Bristol-Myers Squibb (BMY) is trading at is $52.51, which is out of the analyst’s predicted range.